Lab study tests Iron-Binding drug on Parkinson's and ALS cells
NCT ID NCT02880033
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at how the drug deferiprone affects blood cells from 90 people with Parkinson's disease, ALS, or healthy volunteers. Researchers measured markers of oxidative stress and iron levels in the lab. The goal was to better understand these diseases, not to treat patients directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
deferiprone
What this could lead to
If successful, this could help researchers understand how iron and oxidative stress contribute to Parkinson's and ALS, potentially guiding future treatments.
What could go wrong
This is a very early, lab-based study using cells from patients, not a treatment trial. Results may not translate to real-world benefits for patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Roger Salengro, CHRU de Lille
Lille, France